Does Wegovy affect heart rate, and when should you act?

Step 1, What happens in the first weeks of treatment

When semaglutide enters the body, it acts on GLP-1 receptors in the gut, the pancreas and the central nervous system. One downstream effect is a mild increase in sympathetic nervous system activity, which can nudge resting heart rate upward. In the STEP 1 trial (a 68-week study of 1,961 adults published in the New England Journal of Medicine) the semaglutide group showed a small but measurable rise in mean resting heart rate compared with placebo. The absolute numbers were modest: most analyses put the average increase at roughly 1–4 beats per minute. That is within the normal variation most people experience across a single day, but it is real, and it is worth tracking.

For the majority of people, this shows up as a subtle awareness of the heart working slightly harder at rest. Some describe it as a feeling that their pulse is more noticeable than usual. It is not the same as palpitations in the clinical sense, and it does not indicate that anything has gone wrong. That said, if you notice your resting heart rate sitting consistently above 100 bpm, or if it feels fast and irregular, that distinction matters and warrants a call to your GP or prescriber. The detailed page on a fast heart rate with Wegovy covers the thresholds worth keeping in mind.

Step 2, What changes as the dose increases

Wegovy is titrated gradually: the prescribing schedule starts at 0.25 mg and steps up approximately every four weeks, reaching 2.4 mg as the standard maintenance dose. For some people, heart rate nudges up a little more after each increase, then settles again within a couple of weeks. This staircase pattern reflects the body adjusting to a higher level of GLP-1 receptor activation.

Staying well hydrated matters here. GI side effects (nausea, vomiting, reduced appetite) are most pronounced during dose escalation, and dehydration from vomiting can cause a secondary rise in heart rate that has nothing to do with semaglutide's direct mechanism. The two causes can overlap, which is why noting whether heart rate changes arrive alongside GI symptoms is useful context for your prescriber. The broader picture of semaglutide and heart rate looks at both mechanisms together. If you are tracking your pulse at home, a consistent reading first thing in the morning, before you sit up, gives the cleanest baseline figure.

The NHS semaglutide medicines page lists palpitations among the side effects to report to a pharmacist or GP, worth bookmarking if you are newly started.

Step 3, Knowing when a heart rate change needs medical attention

Most of the heart rate changes associated with Wegovy are benign, self-limiting and unlikely to require any adjustment. A few presentations, though, call for prompt review. Get same-day medical help if you experience:

• A heart rate that feels fast and irregular at the same time
• Palpitations alongside chest tightness, pain, or pressure
• Breathlessness that is disproportionate to what you are doing
• Dizziness or near-fainting, particularly on standing
• A resting heart rate consistently above 100 bpm when sitting quietly

None of these are common on Wegovy, but the combination of symptoms matters more than any single reading. Pre-existing conditions (atrial fibrillation, previous cardiac events, or medications that already affect heart rate) make an upfront conversation with a prescriber especially important. On that point, whether Wegovy affects heart rate in a clinically meaningful way depends significantly on individual cardiovascular history, which is exactly the kind of detail a named prescriber needs before recommending this treatment.

If you are already on treatment and have questions about a specific reading, our aftercare team is available seven days a week.

Wegovy, heart rate and the cardiovascular picture more broadly

There is an important distinction worth drawing: a small rise in resting heart rate is a known pharmacological effect of semaglutide, but Wegovy also holds a separate UK authorisation for reducing the risk of major cardiovascular events in eligible adults. The SELECT trial demonstrated this cardiovascular benefit in adults with established heart disease and obesity, so the medicine's overall relationship with the heart is more nuanced than the resting heart rate figure alone suggests. Treating obesity itself reduces long-term cardiovascular risk, and for the right patient profile, the net cardiac picture on Wegovy is favourable.

That nuance is part of why treatment is not a one-size prescription. People who are pregnant, breastfeeding, or planning a pregnancy are not candidates for Wegovy. Under-18s are not licensed for it either. And for anyone with complex cardiac history, the prescriber assessment is the step that determines whether the cardiovascular benefit outweighs any concern about a modest heart rate rise. You can read more about one particular aspect of this on our page covering whether Wegovy lowers heart rate, a question that reflects the nuance here well.

If you are weighing up treatment or want a prescriber to look at your specific health picture, starting a free consultation with our clinical team is the practical next step. And for a broader look at the costs involved in private treatment, the Wegovy price comparison page covers what a legitimate private prescription typically includes in the UK.